Peripherally acting μ‐opioid antagonist for the treatment of opioid‐induced constipation: Systematic review and meta‐analysis

@article{Nishie2019PeripherallyA,
  title={Peripherally acting μ‐opioid antagonist for the treatment of opioid‐induced constipation: Systematic review and meta‐analysis},
  author={K. Nishie and Shuhei Yamamoto and T. Yamaga and N. Horigome and M. Hanaoka},
  journal={Journal of Gastroenterology and Hepatology},
  year={2019},
  volume={34},
  pages={818 - 829}
}
Opioid‐induced constipation (OIC) is a frequent adverse event (AE) that impairs patients' quality of life (QOL). Peripherally acting μ‐opioid receptor antagonists (PAMORAs) have been recognized as a treatment option for OIC, but the effect consistent across the studies has not been evaluated. 
5 Citations

References

SHOWING 1-10 OF 52 REFERENCES
Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid‐induced constipation
  • 134
  • PDF
Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
  • N. Katakami, T. Harada, +7 authors N. Boku
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017
  • 53
Opioid-Induced Bowel Dysfunction
  • 26
...
1
2
3
4
5
...